Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets
Retrieved on:
Tuesday, August 1, 2023
Biotechnology, Professional Services, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Finance, GSK, Therapy, Investment, Cytotoxicity, Immunology, Chimera, Autoimmunity, Antibody, Patient, Immune system, Longwood, Pharmacology, Founding, Pharmaceutical industry, Solu
This platform is designed to unlock antibody-intractable cell surface targets and build next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.
Key Points:
- This platform is designed to unlock antibody-intractable cell surface targets and build next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.
- In return for the license, GSK received equity in Solu and will receive milestones and royalties on products derived from the CyTaC platform.
- “Antibody therapeutics have had tremendous success across multiple disease areas, however, there is still tremendous untapped potential,” commented Dr. Westphal.
- “We’re excited to partner with the Solu team as they develop new medicines for patients who otherwise have limited therapeutic options.”